For most of medicine, prior authorization is a chronic problem. In endocrinology, it became acute almost overnight. The drug class is GLP-1 agonists — semaglutide, tirzepatide, and related agents — and the authorization picture shifted from barely a consideration to a near-universal gate in roughly two years.
The challenge isn’t just the new volume. It’s that the criteria are poorly standardized across payers, the rejection rate is high, and practices that weren’t running PA infrastructure for this drug class suddenly need it for almost every patient.
The numbers in endocrinology
Penn LDI and AJMC tracking of Medicare Part D GLP-1 coverage found:
- Fewer than 5% of GLP-1 prescriptions required prior authorization before 2024.
- By late 2025, that figure had reached approximately 100% for Medicare patients.
- An October 2024 analysis found a ~60.5% GLP-1 claim rejection rate — a majority of first-pass submissions.
These numbers sit on top of the load every physician carries: 39 authorizations per week, roughly 13 hours lost to them, and 82% of physicians saying PA can lead patients to abandon treatment (AMA 2024). In endocrinology, that general friction is now applied to one of the highest-volume drug classes in the practice.
Why endocrinology is different
- Sudden wall, not gradual ramp. Practices weren’t built for PA on GLP-1s; the infrastructure — staff, templates, tracking — didn’t exist at scale when the requirement appeared.
- High rejection on first pass. A 60% rejection rate doesn’t mean most are ultimately denied — it means most are coming back with documentation requests, adding a second or third loop to each authorization.
- Poorly standardized criteria. Each payer has its own threshold for BMI, comorbidity documentation, prior weight-loss treatment history, and duration of conservative management. The same patient needs a different packet for each plan.
- Ongoing re-authorizations. GLP-1 therapy for chronic weight management or type 2 diabetes doesn’t end at one approval; payers require periodic re-authorization as treatment continues.
- Thyroid and adrenal gating. Beyond GLP-1s, endocrinology also contends with PA on injectable insulin analogues, continuous glucose monitors, and some thyroid treatments — but the GLP-1 surge is the acute pressure point.
What it costs
The cost is concentrated in two places. For patients, it’s abandoned treatment: when the first submission is rejected and the follow-up loop takes weeks, patients who could benefit from effective weight management or tighter glycemic control are waiting. For the practice, it’s staff time that wasn’t planned for — assembling new documentation packets for a drug class that effectively became PA-required overnight, at roughly $10.81 per manually processed authorization (CAQH 2023), multiplied across a surge in prescribing volume.
How to cut the wait
The GLP-1 authorization packet is structured documentation — BMI, comorbidity history, prior treatment record — which is exactly what software should assemble. Artificer Health:
- Builds the clinical packet from the patient record, including the comorbidity documentation and prior-treatment history each payer’s GLP-1 criteria require.
- Matches it to the payer’s criteria — so a 60% first-pass rejection rate becomes a first-pass approval rate, eliminating the documentation-request loops.
- Tracks re-authorizations so ongoing therapy doesn’t lapse while the practice is managing the next wave of new authorizations.
The GLP-1 wall didn’t take two years to go up. It shouldn’t take two years of staff overhead to get through it.
Further reading: GLP-1 Prior Authorization Guide: Requirements by Drug, Indication, and Payer (2025–2026) — T2D, weight management, and CV risk pathways with payer-specific criteria for Ozempic, Wegovy, Mounjaro, Zepbound, and more.
Sources: Penn LDI / AJMC GLP-1 coverage analyses (2024–2025); AMA 2024 Prior Authorization Physician Survey (n=1,000); CAQH 2023 Index.